Search Result
Results for "
anti-tumor effect
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-160160
-
|
|
PPAR
|
Cancer
|
|
BAY-5516 is a inverse-agonist o PPARG, with the IC50 value of 6.1±3.6 nM that has anti-tumor effect .
|
-
-
- HY-N1984
-
|
Qing Hao acid; Artemisinic acid; Arteannuic acid
|
Bacterial
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Artemisinic acid (Qing Hao acid), an amorphane sesquiterpene isolated from Artemisia annua L., possesses a variety of pharmacological activity, such as antimalarial activity, anti-tumor activity, antipyretic effect, antibacterial activity, allelopathy effect and anti-adipogenesis effect .
|
-
-
- HY-N4109
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Decursinol, isolated from the roots of Angelica gigas, possesses antinociceptive effect with orally bioavailability. Decursinol possesses anti-tumor and anti-metastasis activity .
|
-
-
- HY-112624F1
-
|
|
Fluorescent Dye
|
Cancer
|
|
CY5-Dextran (MW 4000) is a fluorescent dye that consists of CY5 (HY-D0821) and Dextran (HY-112624) (Ex=633 nm; Em=670 nm). CY5-Dextran (MW 4000) exhibits an anti-tumor effect. CY5-Dextran (MW 4000) can be used to visualize the specific subcellular distribution of dextran at the nanoscale .
|
-
-
- HY-160263S
-
-
-
- HY-107226
-
|
|
Others
|
Cancer
|
|
Crovatin, isolated from the stem bark of C. oblongifolius, shows anti-tumor effect .
|
-
-
- HY-N8840
-
|
|
Others
|
Cancer
|
|
Laricitrin (compound 4) is an O-methylated flavonol, a type of flavonoid, that has anti-tumor effect .
|
-
-
- HY-N3512
-
|
|
Others
|
Cancer
|
|
Wilfornine A is a natural product that can be isolated from Schisandra sphenanthera. Wilfornine A has anti-tumor effect .
|
-
-
- HY-N8204
-
-
-
- HY-163093
-
|
|
Others
|
Cancer
|
|
ATX inhibitor 24 is a potent ATX inhibitor with IC50 of 7.51±0.72 nM that has anti-tumor effect .
|
-
-
- HY-108520
-
|
|
RAR/RXR
Apoptosis
|
Cancer
|
|
HX630 is a potent retinoic acid X receptor (RXR) agonist, can induce apoptosis, has anti-tumor effect, and can be used in Cushing's disease research .
|
-
-
- HY-129467
-
|
2-Hydroxyoleic acid; 2-OHOA
|
Apoptosis
|
Cancer
|
|
(Rac)-Idroxioleic acid (2-Hydroxyoleic acid) is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid has anti-tumor effect .
|
-
-
- HY-162240
-
-
-
- HY-N6049
-
-
-
- HY-108986
-
|
|
Sirtuin
SARS-CoV
|
Cancer
|
|
JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2 .
|
-
-
- HY-N8684
-
|
|
Others
|
Cancer
|
|
Chrysin 6-C-glucoside (compound 14) is an active product that can be extrated from Psidium guajava. Chrysin 6-C-glucoside has anti-tumor effect .
|
-
-
- HY-156856
-
|
|
ADC Cytotoxin
|
Cancer
|
|
FL118-14-Propanol is a FL118 derivative. FL118-14-Propanol synthesized ADC molecule has good anti-tumor effect in mice .
|
-
-
- HY-157435
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
PELI1-IN-1 (compound 3d) is a potent inhibitor of PELI1, E3 ubiquitin ligase. PELI1-IN-1 has anti-tumor effect .
|
-
-
- HY-119034
-
|
|
Others
|
Cancer
|
|
AD-20 is an o-methoxyphenylacetyl dehydroalanine derivative. AD-20 can not only reduce the acute and subchronic toxicity of Doxorubicin (HY-15142A), but also enhance its anti-tumor effect .
|
-
-
- HY-112030
-
|
Potassium tetrachloroplatinate(Ⅱ)
|
Others
|
Cancer
|
|
Dipotassium tetrachloroplatinate(Potassium tetrachloroplatinate(Ⅱ)) is an important reagent for the preparation of other platinum coordination complexes. Dipotassium tetrachloroplatinate can be used as a radiosensitizer to enhance the killing effect of hyperthermia. Dipotassium tetrachloroplatinate has anti-tumor activity .
|
-
-
- HY-162064
-
|
|
VEGFR
|
Cancer
|
|
T-1-MBHEPA is a potent inhibitor of VEGFR-2, with the IC50 value of 0.121±0.051 μM. T-1-MBHEPA has anti-tumor and anti-angiogenic effect .
|
-
-
- HY-161075
-
|
|
Microtubule/Tubulin
Ferroptosis
|
Cancer
|
|
Microtubule inhibitor 8 (MP-HJ-1b) is a potent inhibitor of microtubule. Microtubule inhibitor 8 triggers cell death through ferroptosis. Microtubule inhibitor 8 has anti-tumor effect .
|
-
-
- HY-163295
-
|
|
ADC Cytotoxin
Btk
|
Cancer
|
|
BTK degrader-1 (compound 1) is a Bruton’s tyrosine kinase (BTK) bifunctional degrader that can be conjugated with CD79b. BTK degrader-1 (compound 1) has anti-tumor effect .
|
-
-
- HY-N4109R
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Decursinol (Standard) is the analytical standard of Decursinol. This product is intended for research and analytical applications. Decursinol, isolated from the roots of Angelica gigas, possesses antinociceptive effect with orally bioavailability. Decursinol possesses anti-tumor and anti-metastasis activity .
|
-
-
- HY-N10781
-
|
|
Cholinesterase (ChE)
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Isograndifoliol is a selective inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 0.9 μM. And Isograndifoliol moderately inhibits acetylcholinesterase (AChE) with an IC50 value of 342.9 μM. Isograndifoliol also has vasorelaxant effect and anti-tumor effect. Isograndifoliol can be used for research against dementia caused by neurodegenerative diseases .
|
-
-
- HY-120187
-
|
|
Others
|
Others
|
|
DDCPPB-Glu (compound 3a) is a compound with anti-tumor activity, which has the activity of inhibiting tumor cell growth and prolonging survival. DDCPPB-Glu has growth inhibition effect on various tumor cell lines, can increase the survival time of leukemia mice, and has inhibitory effect on tumors such as colon cancer and lung cancer.
|
-
-
- HY-N0211
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
Cyasterone, a natural EGFR inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors .
|
-
-
- HY-117591
-
|
|
Elastase
|
Inflammation/Immunology
Cancer
|
|
L-684248 is an inhibitor of human leukocyte elastase (HLE). L-684248 exerts its inhibitory effect on HLE by forming a covalent bond with the active site of the enzyme, showing potential value for applications in anti-inflammatory and anti-tumor research .
|
-
-
- HY-126775
-
|
|
Others
|
Cancer
|
|
Xenoclauxin is a secondary metabolite isolated from certain species of the Penicillium genus, which exhibits an inhibitory effect on the proliferation of tumor cells. Xenoclauxin affects cellular energy metabolism, particularly by inhibiting ATP synthesis in the mitochondria. Xenoclauxin can be used for anti-tumor research .
|
-
-
- HY-143280
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase II inhibitor 4 (compound E17) is a potent Topoisomerase II inhibitor. Topoisomerase II inhibitor 4 triggers G2/M cell cycle arrest and shows anti-tumor activity with strong cytotoxic and anti-proliferative effect .
|
-
-
- HY-149035
-
|
|
Others
|
Cancer
|
|
PAA4 is a methide carbon-centered polynuclear Au(I) clusters. PAA4 shows antiproliferative activity. PAA4 increases the expression of pH2AX in a time dependent manner. PAA4 shows anti-tumor effect in orthotopic bladder cancer mouse model .
|
-
-
- HY-N3665
-
|
|
Tyrosinase
|
Cancer
|
|
Cyclocommunol is a prenylflavonoid with antityrosinase and antiplatelet activitie, can be solated from breadfruit. Cyclocommunol exerts anti-tumor activity and inhibits the growth of human hepatoma and gastric cancer cells with IC50 values between 16 and 80 µM. Cyclocommunol shows proapoptotic effect on oral squamous cell carcinoma (OSCC) .
|
-
-
- HY-156019
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-10 (Compound 4i) is an FGFR1 inhibitor (IC50: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect .
|
-
-
- HY-A0020
-
|
ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
|
VD/VDR
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
|
-
-
- HY-P10652
-
|
|
Wnt
β-catenin
|
Cancer
|
|
hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research .
|
-
-
- HY-103665
-
|
|
STING
|
Cancer
|
|
STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer .
|
-
-
- HY-103665A
-
|
|
STING
|
Cancer
|
|
STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pEC50 of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer .
|
-
-
- HY-113314
-
|
|
Endogenous Metabolite
|
Cancer
|
|
AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pKa of AFMK at physiological pH is 8.7. Antioxidant capacity . AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway .
|
-
-
- HY-N0211R
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
Cyasterone (Standard) is the analytical standard of Cyasterone. This product is intended for research and analytical applications. Cyasterone, a natural EGFR inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors .
|
-
-
- HY-15505
-
|
JNJ 3026582
|
p38 MAPK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity .
|
-
-
- HY-143265
-
|
|
Topoisomerase
Apoptosis
Caspase
|
Cancer
|
|
Topoisomerase I inhibitor 2 (ZML-8) is a highly selective inhibitor of DNA topoisomerase I (Top1). Topoisomerase I inhibitor 2 inhibits Top1 activity and results DNA damage. Topoisomerase I inhibitor 2 blocks G2/M phase and induces apoptosis, exhibits anti-tumor effect .
|
-
-
- HY-153396
-
|
|
Ceramidase
|
Cancer
|
|
Acid Ceramidase-IN-2 (compound 1) is an acid ceramidase inhibitor with potentially antiproliferative and cytostatic activities. Moreover, human acid ceramidase is overexpressed in prostate cancer cells, indicating potential anti-tumor effect of Acid Ceramidase-IN-2. And Acid Ceramidase-IN-2 hydrolysis can be inhibited by 3 a-ketoamides GT85, GT98 and GT99 inhibits in vitro .
|
-
-
- HY-153450
-
|
|
Protein Arginine Deiminase
|
Cancer
|
|
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research .
|
-
-
- HY-156569
-
|
|
DGK
|
Inflammation/Immunology
Cancer
|
|
DGKα-IN-2 (example 48) is a DGKα inhibitor with the IC50 of 0.9 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
|
-
-
- HY-156570
-
|
|
DGK
|
Inflammation/Immunology
Cancer
|
|
DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC50 of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
|
-
-
- HY-156571
-
|
|
DGK
|
Cancer
|
|
DGKα-IN-4 (example 432) is a DGKα inhibitor with the IC50 of 0.1 nM, extracted from patent WO2021105117. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-3 has the potential for cancer and immunology study.
|
-
-
- HY-117273
-
|
|
Raf
Autophagy
|
Cancer
|
|
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity .
|
-
-
- HY-128355A
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Others
Cancer
|
|
(R)-IDO/TDO-IN-1 (compound 25) is an indoleamine-2,3-dioxygenase (IDO) inhibitor, with good pharmacokinetic properties. (R)-IDO/TDO-IN-1 exhibits anti-tumor activity in MC38 xenograft model. (R)-IDO/TDO-IN-1 shows synergistic effect with anti-PD-1 monoclonal antibody (SHR-1210) .
|
-
-
- HY-157765
-
|
|
PROTACs
Estrogen Receptor/ERR
|
Cancer
|
|
PROTAC ERα Degrader-6 (compound A3) is a potent PROTAC degrader of ERα, with DC50 of 0.12 μM. PROTAC ERα Degrader-6 has anti-tumor effect. PROTAC ERα Degrader-6 is a fluorescent probes with Em of 582 nm that enable real-time visualization of ERα protein degradation .
|
-
-
- HY-A0020R
-
|
|
VD/VDR
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Eldecalcitol (Standard) is the analytical standard of Eldecalcitol. This product is intended for research and analytical applications. Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
|
-
- HY-161853
-
|
|
Others
|
Others
|
|
TX-2552 is an orally active tyrosine DNA phosphodiesterase 1 (TDP1) inhibitor with an IC50 value of 0.62 μM. TX-2552 can enhance the clastogenic activity of Topotecan (HY-13768) in mouse bone marrow cells, as well as the anti-tumor effect of Topotecan (HY-13768) in Krebs-2 ascites tumor mice .
|
-
- HY-162382
-
|
|
PI3K
Akt
mTOR
|
Cancer
|
|
KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 can inhibit the PI3K signaling pathway, reduce downstream AKT and mTOR phosphorylation, and reduces the expression of Ki67. The anti-tumor effect of KTC1101 has a dual mechanism of action: directly inhibiting tumor cell growth and dynamically enhancing immune response .
|
-
- HY-161886
-
|
|
Others
|
Cancer
|
|
SMARCA2-IN-7 (compound 12), a dual inhibitor of BRM and BRG1 (IC50 < 0.005 for both), has an anti-tumor proliferation effect that inhibits BRG1-deleted SKMEL5 tumor proliferation with a cell proliferation activity AAC50 of 13 nM in SKMEL5. The cell proliferation activity AAC50 of KRT880 in H1299 cells was 42 nM .
|
-
- HY-N2515
-
|
|
NF-κB
PI3K
JAK
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures .
Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB .
Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis .
Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
|
-
- HY-N0405
-
|
|
TNF Receptor
Interleukin Related
|
Neurological Disease
Cancer
|
|
Orientin is a neuroprotective agentinhibits which has anti-inflammation, anti-oxidative, anti-tumor, and cardio protection properties. Orientin inhibits the levels of IL-6, IL-1β and TNF-α. Orientin increases IL-10 level. Orientin exhibits neuroprotective effect by inhibits TLR4 and NF-kappa B signaling pathway. Orientin can used in study neuropathic pain .
|
-
- HY-149374
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 36 (Compound 10) is a novel and potent tubulin inhibitor and inhibits the polymerization of microtubular protein then induces apoptosis with an IC50 value of 1.5±0.1 μM. Tubulin inhibitor 36 (Compound 10) has significant anti-mitotic effect and exhibits activities against glioblastoma cells. Tubulin inhibitor 36 (Compound 10) has anti-tumor effects and can be used for glioblastoma multiforme (GBM) research .
|
-
- HY-121372
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
Lactandrate is a D-high nitrogen steroid alkylating agent. It can interact with the ligand-binding domain (LBD) of estrogen receptor-alpha (ERα). Lactandrate has a growth inhibitory effect on breast cancer cells, with a GI50 value ranging from 5 to 65 μM. It shows anti-tumor activity in mouse breast tumors (MXT and CD8F1) as well as in human xenograft MX-1 .
|
-
- HY-119940
-
|
(rel)-MC180295
|
CDK
|
Cancer
|
|
MC180295 ((rel)-MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect .
|
-
- HY-107063
-
|
10-Undecen-1-yl-thiopseudourea iodide
|
Others
|
Cancer
|
|
AHR-1911 (10-Undecen-1-yl-Thiopseudourea Iodide;Isothiuronium) is a thiourea-based anti-inflammatory and anti-tumor agent that has an improving effect on burned skin. AHR-1911 produces histamine-like effects when injected intradermally and may reduce arterial pressure in anesthetized dogs. AHR-1911 inhibits tumor growth and reduces microsomal and C-polysome protein synthesis .
|
-
- HY-P5557
-
|
|
Bacterial
Necroptosis
|
Cancer
|
|
TP4 (Nile tilapia piscidin) is an orally active piscidin-like antimicrobial peptide. TP4 inhibits multiple gram positive and negative strains (MIC: 0.03-10 μg/mL). TP4 shows hemolytic activities. TP4 enhances immune response, antioxidant activity, and intestinal health against bacterial infections. TP4 also has anti-tumor effect, and induces necrosis by triggering mitochondrial dysfunction in cancer cells .
|
-
- HY-16160
-
|
|
Autophagy
ICMT
|
Cancer
|
|
Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
|
-
- HY-15163A
-
|
|
FLT3
JAK
CDK
|
Cancer
|
|
Zotiraciclib hydrochloride is a novel small molecule multi-target enzyme inhibitor with activity in inhibiting tumor growth. Zotiraciclib hydrochloride exerts its anti-tumor effect by reducing the level of Myc through inhibiting cyclin-dependent kinase 9 (CDK9). Zotiraciclib hydrochloride may be useful for inhibiting cancers that cross the blood-brain barrier. The high protein level of MCL-1 of Zotiraciclib hydrochloride is associated with survival, suggesting that it may serve as a prognostic factor and inhibitory target in further studies .
|
-
- HY-114246
-
|
|
Others
|
Cancer
|
|
ONC1-13B is a potent androgen receptor (AR) antagonist with the activity of effectively inhibiting PSA expression in prostate cancer cells. ONC1-13B can effectively inhibit PSA expression and prostate cancer cell proliferation under DHT stimulation. ONC1-13B exerts its anti-tumor effect by preventing androgen from binding to AR and its nuclear translocation .
|
-
- HY-N2515R
-
|
|
NF-κB
PI3K
JAK
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Ginsenoside Rk1 (Standard) is the analytical standard of Ginsenoside Rk1. This product is intended for research and analytical applications. Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures .
Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB .
Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis .
Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
|
-
- HY-U00279B
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Nitracrine hydrochloride is a platinum-based antineoplastic drug with selective toxicity to hypoxic cells. Nitracrine hydrochloride exhibits significant cytotoxicity against the Chinese hamster ovary cell line AA8 under hypoxic conditions and is approximately 100,000 times more potent than misonidazole. Nitracrine hydrochloride exerts its effect by binding to the insertion of DNA and forming covalent adducts. The cytotoxicity of Nitracrine hydrochloride under hypoxic conditions is related to its reductive metabolism to form alkylated substances. At the same time, it may enhance the reactivity to DNA through the insertion of DNA, thereby improving the efficacy. Nitracrine hydrochloride can also inhibit RNA synthesis, contributing to its anti-tumor effect .
|
-
- HY-N1346
-
Robinin
2 Publications Verification
|
Toll-like Receptor (TLR)
Apoptosis
|
Inflammation/Immunology
|
|
Robinin is a flavonoid that can be extracted from the leaves of purple cowpea, inhibiting TGF-β, TLR4/NF-κB and TLR2-PI3k-AKT signaling pathways. Robinin exerts anti-inflammatory and anti-tumor effects. The combination of Robinin and Methotrexate (HY-14519) reduces inflammation in experimental arthritis, Robinin can decrease the Doxorubicin (HY-15142A) induced cardiac toxicity effect .
|
-
- HY-N0405R
-
|
|
TNF Receptor
Interleukin Related
|
Neurological Disease
Cancer
|
|
Orientin (Standard) is the analytical standard of Orientin. This product is intended for research and analytical applications. Orientin is a neuroprotective agentinhibits which has anti-inflammation, anti-oxidative, anti-tumor, and cardio protection properties. Orientin inhibits the levels of IL-6, IL-1β and TNF-α. Orientin increases IL-10 level. Orientin exhibits neuroprotective effect by inhibits TLR4 and NF-kappa B signaling pathway. Orientin can used in study neuropathic pain .
|
-
- HY-17576
-
-
- HY-119527
-
-
- HY-N1366
-
|
Methylumbelliferone
|
Others
|
Cancer
|
|
Herniarin is a natural coumarin occurs in some flowering plants, with antitumor effect.
|
-
- HY-159563
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-va-mac-SN38 is a drug-linker conjugate for ADC. Mal-va-mac-SN38 contains a ADC cytotoxin SN-38 (HY-13704) and a linker (HY-126364). Mal-va-mac-SN38 can rapidly and covalently bind with endogenous albumin in vivo, resulting in the formation of HSA-va-mac-SN38. Mal-va-mac-SN38 demonstrates exceptional stability in human plasma, and has anti-tumor and anti-metastasis effect .
|
-
- HY-123371
-
|
|
Others
|
Cancer
|
|
Ro 07-1902 is an effective antitumor potentiator that can significantly enhance the antitumor effect of CCNU against KHT sarcoma at low doses .
|
-
- HY-129234
-
-
- HY-N1346R
-
|
|
Toll-like Receptor (TLR)
Apoptosis
|
Inflammation/Immunology
|
|
Robinin (Standard) is the analytical standard of Robinin. This product is intended for research and analytical applications. Robinin is a flavonoid that can be extracted from the leaves of purple cowpea, inhibiting TGF-β, TLR4/NF-κB and TLR2-PI3k-AKT signaling pathways. Robinin exerts anti-inflammatory and anti-tumor effects. The combination of Robinin and Methotrexate (HY-14519) reduces inflammation in experimental arthritis, Robinin can decrease the Doxorubicin (HY-15142A) induced cardiac toxicity effect .
|
-
- HY-129071
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 µM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo .
|
-
- HY-105969
-
|
NSC-29630; 3',5'-Dichloromethotrexate
|
Others
|
Cancer
|
|
Dichloromethotrexate (NSC-29630), an orally active antitumor agent, shows antitumor effect against L1210 leukemia and C3H lymphosarcoma in mice .
|
-
- HY-149916
-
|
|
Adenosine Receptor
|
Cancer
|
|
A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC50=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2) .
|
-
- HY-19825
-
|
|
Topoisomerase
ADC Cytotoxin
Antibiotic
|
Cancer
|
|
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II .
|
-
- HY-131126S
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Metolcarb-d3 is the deuterium labeled Herniarin. Herniarin is a natural coumarin occurs in some flowering plants, with antitumor effect.
|
-
- HY-N1366A
-
|
|
Others
|
Cancer
|
|
Herniarin (Standard) is a standard product of Herniarin. Herniarin is a natural coumarin occurs in some flowering plants, with antitumor effect .
|
-
- HY-162003
-
|
|
Histone Methyltransferase
|
Cancer
|
|
DCPT1061 potently inhibits PRMT1, PRMT6 and PRMT8 in vitro with less inhibitory effect on PRMT3, PRMT4, and PRMT5 or other epigenetic enzymes. DCPT1061 has antitumor effect .
|
-
- HY-W440983
-
|
PC(18:0/22:6); DHA-PC; 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine
|
PPAR
|
Cardiovascular Disease
Cancer
|
|
SDPC (DHA-PC) is a new generation of omega-3 lipids, which contains an ester bond linking DHA at the sn-2 position of phospholipid. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine exerts anti-angiogenesis effect through activating PPARγ. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine significantly declines the proliferation, migration, tube formation of human umbilical vein endothelial cells. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine has the potential for anti-tumor angiogenesis research .
|
-
- HY-162003A
-
|
|
Histone Methyltransferase
|
Cancer
|
|
DCPT1061 hydrochloride has a strong inhibitory effect on PRMT1, PRMT6, and PRMT8 in vitro, The epigenetic enzymes such as PRMT3, PRMT4 and PRMT5 had little inhibitory effect. DCPT1061 hydrochloride has antitumor effects .
|
-
- HY-129071R
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Vindesine (sulfate) (Standard) is the analytical standard of Vindesine (sulfate). This product is intended for research and analytical applications. Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 μM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo .
|
-
- HY-151295
-
|
|
Others
|
Cancer
|
|
Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC50 value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer .
|
-
- HY-110215
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
XD14 is a potent BET inhibitor with antitumor effect. It binds to BRD2, BRD3, and BRD4 with Kds of 170, 380, and 160 nM, respectively .
|
-
- HY-164529
-
|
|
Raf
Ras
MEK
ERK
VEGFR
Tie
c-Fms
|
Cancer
|
|
SJ-C1044 is an orally available pan-RAF inhibitor with immunomodulatory and anti-tumor activities. SJ-C1044 inhibits wild-type BRAF, wild-type CRAF, and BRAF (V600E) with IC50 values ??of 331, 257, and 187 nM, respectively. SJ-C1044 inhibits tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. In addition, SJ-C1044 also has a certain inhibitory effect on VEGFR2, TIE2, and CSF1R, with IC50 values ??of 100, 23, and 235 nM, respectively. SJ-C1044 improves the tumor immune microenvironment by inhibiting angiogenesis and regulating macrophage function. SJ-C1044 can be used in the study of colorectal cancer .
|
-
- HY-N1318S
-
-
- HY-156411
-
|
|
Bacterial
|
Cancer
|
|
NR-NO2 is a potential drug with targeted release and imaging-based guidance in antitumor research. NR-NO2 has an anti-bacterial effect .
|
-
- HY-N7271
-
|
|
Others
|
Cancer
|
|
Solanidine is a cholestane alkaloid isolated from several potato species including Solanum demissum, Solanum acaule, and Solanum tuberosum. Solanidine can inhibit proliferation and exhibit obvious antitumor effect .
|
-
- HY-163081
-
|
|
PARP
|
Cancer
|
|
PARP7-IN-17 is a potent inhibitor of PARP7 with IC50 of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .
|
-
- HY-59208
-
|
Kynurine
|
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
4-Quinolone (Kynurine) is a quinoline derivative. Kynurine pathway modulates tryptophan metabolism and involves in neuroprotective effect. Kynurine promotes tumor cell survival and motility by suppressing antitumor immune .
|
-
- HY-126048
-
|
|
MEK
|
Cancer
|
|
JTP-70902, a p15 INK4b-inductive compound, is a MEK1/2 inhibitor. JTP-70902 exhibits potent antitumor effect .
|
-
- HY-163607
-
|
|
Apoptosis
NF-κB
|
Cancer
|
|
SpiD3 is a novel spirocyclic dimer. SpiD3 shows antitumor effect and induces cell apoptosis in malignant B cells. SpiD3 can be used for study of chronic lymphocytic leukemia .
|
-
- HY-B0971
-
|
Prophenpyridamine maleate; Tripoton maleate; Pheniramine maleate
|
Histamine Receptor
Apoptosis
|
Inflammation/Immunology
Endocrinology
|
|
Pheniramine (Prophenpyridamine; Tripoton) maleate is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine maleate displays antitumor effect and induces leukemia cells apoptosis. Pheniramine maleate is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .
|
-
- HY-B0971A
-
|
Prophenpyridamine; Tripoton; Pheniramine solution
|
Histamine Receptor
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Pheniramine (Prophenpyridamine;Tripoton) is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine displays antitumor effect and induces leukemia cells apoptosis. Pheniramine is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .
|
-
- HY-N1318
-
-
- HY-160409
-
|
|
Others
|
Cancer
|
|
TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with PARP inhibitors. TopBP1-IN-1 has antitumor activity .
|
-
- HY-125117
-
|
|
DNA/RNA Synthesis
Bacterial
|
Infection
Cancer
|
|
Simocyclinone D8 is an anthracycline antibiotic with antibacterial and antitumor activity against Gram-positive bacteria. Simocyclinone D8 inhibits DNA gyrase and thus has an inhibitory effect on a variety of tumor cell lines .
|
-
- HY-152468
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-83 is an activator of pro-apoptotic protein BAX and has significant anti-proliferation effect on tumor cells. Antiumor agent-83 mediates cell Apoptosis by inducing the conformational activation of BAX and has inhibitory effect on A549 cell cycle. Antiumor agent-83 has good metabolic stability and CYPs spectrum in vitro .
|
-
- HY-115941
-
|
|
HDAC
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
HDAC-IN-9 is a potent and selective tubulin and HDAC dual inhibitor. HDAC-IN-9 inhibits the invasion and migration of A549 cells. HDAC-IN-9 shows potent antitumor and antiangiogenic effect in vitro and in vivo .
|
-
- HY-146267
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
ERα degrader 5 (Compound 40) is a selective, orally bioavailable estrogen receptor (ER) degrader (SERD) with an EC50 of 1.1 nM against ERα. ERα degrader 5 shows antitumor effect in vivo .
|
-
- HY-161765
-
|
|
HSP
STAT
|
Cancer
|
|
iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .
|
-
- HY-N7698B
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Hexa-N-acetylchitohexaose is an inducer of disease resistance in crop plants, which could elicit an increase of lignification-related and antioxidative enzymes in soybean plants. Hexa-N-acetylchitohexaose is a substrate of lysozyme. Hexa-N-acetylchitohexaose shows antitumor effect .
|
-
- HY-146406
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 52 is a potent anticancer agent. Anticancer agent 52 shows in vitro cytotoxicity. Anticancer agent 52 induces apoptosis. Anticancer agent 52 shows antitumor effect. Anticancer agent 52 has the potential for the research of bladder cancer .
|
-
- HY-110120
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist, with EC50s of 7.2 nM and 4.6 nM for human and mice TLR7, respectively. DSR-6434 has a strong antitumor effect .
|
-
- HY-106364
-
|
Bleomycin PEP; Pepleomycin
|
Antibiotic
|
Cancer
|
|
Peplomycin (Bleomycin PEP; Pepleomycin) is an antibiotic analogue of Bleomycin (HY-108345), with high antitumor effect and less pulmonary toxicity. Peplomycin induce apoptosis in oral squamous carcinoma cell line SSCKN cells and pulmonary fibrosis in rats .
|
-
- HY-10008
-
|
BMS-387032
|
CDK
Apoptosis
|
Cancer
|
|
SNS-032 (BMS-387032) is a potent and selective inhibitor of?CDK2, CDK7, and CDK9 with?IC50s?of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect .
|
-
- HY-123325
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Kapurimycin A1 is an anbitiotic that can be isolated from Streptomyces. Kapurimycin A1 has a significant inhibitory effect on Gram-positive bacteria, exhibits cytotoxicity to cultured mammalian cells, and shows strong antitumor activity against the mouse leukemia P388 cell line .
|
-
- HY-N2150
-
|
|
HDAC
DNA Methyltransferase
DNA/RNA Synthesis
Bacterial
|
Infection
Cancer
|
|
Psammaplin A, a marine metabolite, is a potent inhibitor of HDAC and DNA methyltransferases. Psammaplin A ia a highly potent and selective DAC1 inhibitor with an IC50 of 0.9 nM. Psammaplin A possess the antimicrobial effect on the Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Antitumor Activity .
|
-
- HY-123542
-
|
|
Ser/Thr Protease
Apoptosis
|
Cancer
|
|
ONO-3403 is an orally active serine protease inhibitor. ONO-3403 inhibits the production of TNF-α and nitric oxide induced by LPS. ONO-3403 inhibits the cell growth and induces the apoptosis, and has an antitumor effect on malignant tumors .
|
-
- HY-143435
-
|
|
Apoptosis
|
Cancer
|
|
AG6033 is a potential novel CRBN modulator. AG6033 suppresses various tumor cells by modulating the interactions between CRBN and various antitumor target proteins. AG6033 can cause GSPT1 and IKZF1 degradation. AG6033 induces CRBN-dependent cytotoxic effect .
|
-
- HY-149240
-
|
|
P-glycoprotein
|
Cancer
|
|
Anticancer agent 108 (Compound 3.10) is a potent P-gp inhibitor with significant antitumor activity and less toxicity to normal and pseudonormal cells. Anticancer agent 108 (Compound 3.10) had no acute toxic effect on С57BL/6 mice .
|
-
- HY-N0646
-
|
|
Phosphatase
Endogenous Metabolite
|
Cancer
|
|
Silydianin is an active constituent of Silybium marianum, with exhibit anti-collagenase, antitumor and anti-elastase activities. Silydianin is a natural protein tyrosine phosphatase 1B (PTP1B) with an IC50 of 17.38 μM. Silydianin has inhibitory effect on the in vitro production and release of oxidative products .
|
-
- HY-N2112
-
|
|
PI3K
Akt
Apoptosis
|
Cancer
|
|
Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating PI3K/Akt signaling pathway. Glaucocalyxin A has antitumor effect .
|
-
- HY-W013164
-
|
|
COX
|
Inflammation/Immunology
Cancer
|
|
SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect .
|
-
- HY-145737
-
|
|
PROTACs
Ras
|
Cancer
|
|
PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader with an DC50 of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .
|
-
- HY-168528
-
|
|
P-glycoprotein
|
Cancer
|
|
WS-917 is a potent and orally active ABCB1 modulator. WS-917 enhances ABCB1 ATPase activity. WS-917 significantly enhances the antitumor effect of paclitaxel combined with anti-PD-1 antibody. WS-917 promotes CD8 + T-cell activation .
|
-
- HY-145737A
-
|
|
PROTACs
Ras
|
Cancer
|
|
PROTAC SOS1 degrader-1 (TFA) is a potent PROTAC SOS1 degrader with an DC50 of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .
|
-
- HY-B0220
-
Erythromycin
Maximum Cited Publications
18 Publications Verification
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
- HY-117763
-
|
|
Others
|
Others
|
|
A-39355 is a compound that can overcome multidrug resistance and has the activity of reversing multidrug resistance. A-39355 can enhance the cytotoxicity of antitumor compounds in multidrug-resistant cells, increase the accumulation of compounds in cells, inhibit the efflux of compounds, and compared with calcium antagonists, it has no serious hypotensive effect. Its activity may be unrelated to the ability to block calcium transport.
|
-
- HY-120768
-
|
|
Others
|
Others
|
|
A-30312 is a compound that can overcome multidrug resistance and has the activity of reversing multidrug resistance. A-30312 can enhance the cytotoxicity of antitumor compounds in multidrug-resistant cells, increase the accumulation of compounds in cells, inhibit the efflux of compounds, and compared with calcium antagonists, it has no serious hypotensive effect. Its activity may be unrelated to the ability to block calcium transport.
|
-
- HY-144056
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2) .
|
-
- HY-144055
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-38 is a potent inhibitor of EGFR. EGFR-IN-38 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 4) .
|
-
- HY-144054
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-37 is a potent inhibitor of EGFR. EGFR-IN-37 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 7) .
|
-
- HY-144052
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11) .
|
-
- HY-144051
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-34 is a potent inhibitor of EGFR. EGFR-IN-34 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12) .
|
-
- HY-144050
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13) .
|
-
- HY-W001925
-
|
|
Apoptosis
NF-κB
c-Met/HGFR
Akt
MMP
|
Cancer
|
|
7-Methoxy-1-tetralone is a potent antitumor agent. 7-Methoxy-1-tetralone inhibits cancer cell proliferation and migration, and induces hepatocellular carcinoma cell (HCC) apoptosis. 7-Methoxy-1-tetralone decreased the protein levels of NF-κB, matrix metallopeptidase 2 (MMP2)/MMP9, and p-AKT. 7-Methoxy-1-tetralone showed antitumor activity in nude mice and had no effect on body weight and liver, spleen and organ index .
|
-
- HY-P1812
-
AUNP-12
3 Publications Verification
NP-12
|
PD-1/PD-L1
|
Cancer
|
|
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
|
-
- HY-N6693
-
|
NSC 122023
|
Apoptosis
Antibiotic
Autophagy
Fungal
|
Infection
Others
Cancer
|
|
Valinomycin is a potassium-specific ionophore, the valinomycin-K + complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K + gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research .
|
-
- HY-B0220D
-
|
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Erythromycin thiocyanate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin thiocyanate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin thiocyanate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
- HY-B0220E
-
|
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Erythromycin A dihydrate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin A dihydrate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin A dihydrate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
- HY-138565
-
|
|
YAP
|
Cancer
|
|
K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .
|
-
- HY-B0220B
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Erythromycin gluceptate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin gluceptate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin gluceptate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
- HY-B0220C
-
|
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Erythromycin aspartate is a macrolide antibiotic produced by actinomycete?Streptomyces erythreus?with a broad spectrum of antimicrobial activity. Erythromycin aspartate binds to bacterial 50S ribosomal subunits and inhibits?RNA-dependent protein synthesis?by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin aspartate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
- HY-108875
-
|
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Erythromycin stearate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin stearate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin stearate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
- HY-B0220A
-
|
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Erythromycin lactobionate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin lactobionate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin lactobionate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
- HY-16290
-
|
ZK 230211; BAY86 5044
|
Progesterone Receptor
|
Endocrinology
|
|
Lonaprisan (ZK 230211; BAY86 5044) is an antagonist for progesterone receptor, with IC50 of 3.6 pM and 2.5 pM for PR-A and PR-B, respectively. Lonaprisan exhibits antiprogestagenic activity in rabbits, interrupts early pregnancy in rats, and exhibits antitumor efficacy against DMBA (HY-W011845)-induced mammary tumor. Lonaprisan reveals antiglucocorticoid and antiandrogenic effect .
|
-
- HY-N0646R
-
|
|
Phosphatase
Endogenous Metabolite
|
Cancer
|
|
Silydianin (Standard) is the analytical standard of Silydianin. This product is intended for research and analytical applications. Silydianin is an active constituent of Silybium marianum, with exhibit anti-collagenase, antitumor and anti-elastase activities. Silydianin is a natural protein tyrosine phosphatase 1B (PTP1B) with an IC50 of 17.38?μM. Silydianin has inhibitory effect on the in vitro production and release of oxidative products .
|
-
- HY-B0220F
-
|
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Erythromycin glutamate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin glutamate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin glutamate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
- HY-164503
-
|
NEP010
|
EGFR
|
Cancer
|
|
Neptinib (NEP010) is an orally active derivative of Afatinib (HY-10261) that has stronger antitumor activity than Afatinib (HY-10261) by improving pharmacokinetics. Neptinib has a significant inhibitory effect on tumor growth in mouse non-small cell lung cancer models with different EGFR mutations. Neptinib has a certain inhibitory effect on the EGFR kinase family, with IC50 values ??of 0.24 nM, 7.25 nM, 0.46 nM and 1.79 nM for EGFR wt, EGFR L858R/T790M, EGFR L858R and EGFR T790M, respectively .
|
-
- HY-18285
-
|
|
Casein Kinase
ERK
CDK
|
Cancer
|
|
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC50s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively .
|
-
- HY-P1812A
-
|
NP-12 TFA
|
PD-1/PD-L1
|
Cancer
|
|
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
|
-
- HY-125390
-
|
CL-087
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response . SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity .
|
-
- HY-B0220S2
-
|
|
Bacterial
DNA/RNA Synthesis
Antibiotic
|
Infection
|
|
Erythromycin-d3 is the deuterium labeled Erythromycin[1]. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid. Erythromycin also exhibits antitumor and neuroprotective effect in different fields of research[2][3][4][5].
|
-
- HY-117991
-
|
|
Others
|
Cancer
|
|
DW10075 is a novel, highly selective VEGFR inhibitor that targets the VEGF/VEGF receptor (VEGFR) pathway, which has been shown to be an effective anti-angiogenic approach for cancer therapy. Studies have found that DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3 among 21 kinases, while having no effect on the other 18 kinases, including FGFR and PDGFR. In human umbilical vein endothelial cells (HUVECs), DW10075 significantly prevented VEGF-induced activation of VEGFR and its downstream signaling, thereby inhibiting VEGF-induced HUVEC proliferation. In addition, DW10075 dose-dependently inhibited VEGF-induced HUVEC migration and tube formation, and suppressed angiogenesis in the rat aortic ring model and the chick embryo chorionic membrane model. DW10075 also exhibited antiproliferative activity against 22 different human cancer cell lines, with IC50 values ranging from 2.2 μmol/L (for U87-MG human glioblastoma cells) to 22.2 μmol/L (for A375 melanoma cells). In the nude mouse U87-MG xenograft tumor model, oral administration of DW10075 significantly inhibited tumor growth and reduced the expression of CD31 and Ki67 in tumor tissues. In summary, DW10075 is a potential anti-tumor angiogenesis agent that deserves further development.
|
-
- HY-116624
-
MAZ51
3 Publications Verification
|
VEGFR
Apoptosis
|
Cancer
|
|
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity .
|
-
- HY-135887
-
|
|
Anaplastic lymphoma kinase (ALK)
Apoptosis
Autophagy
|
Cancer
|
|
ZX-29 is a potent and selective ALK inhibitor with an IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR. ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect .
|
-
- HY-155851
-
|
|
Ferroptosis
MDM-2/p53
Glutathione Peroxidase
|
Cancer
|
|
Lepadin E is a significantly cytotoxic ferroptosis inducer that induces iron death through the classical p53-SLC7A11-GPX4 pathway. Lepadin E promoted p53 expression, decreases SLC7A11 and GPX4 levels, and leads to increased ROS and lipid peroxide production, and upregulated ACSL4 expression, thus causes cell death. Lepadin E has significant antitumor effect .
|
-
- HY-152293
-
|
|
VEGFR
ERK
|
Cancer
|
|
EVT801 is an orally active and selective inhibitor of VEGFR-3 (IC50=11 nM), which has antitumor effects. EVT801 inhibits not only VEGF-C-induced human endothelial cell proliferation, but also tumor (lymphatic) angiogenesis in tumor mouse models. EVT801 can reduce tumor hypoxia, immunosuppressive cytokines (CCL4, CCL5) and myeloid derived suppressor cells (MDSC) production. EVT801 has synergistic effect with immune checkpoint therapy (ICT), which improves ICT response rate and has better inhibitory effect on cancer mouse models . EVT801 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-163028
-
|
|
Tim3
|
Cancer
|
|
ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.
ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
|
-
- HY-150596
-
|
|
Apoptosis
Bcl-2 Family
JNK
|
Cancer
|
|
CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity .
|
-
- HY-P5910
-
|
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .
|
-
- HY-115904
-
|
|
CDK
FLT3
|
Cancer
|
|
FLT3/CDK4-IN-1 is a potent, high selective and orally active FLT3/CDK4 dual inhibitor (IC50=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo .
|
-
- HY-155730
-
|
|
PI3K
|
Cancer
|
|
PI3K-IN-41 (compound 2) is a photocaged compound, as well as a photocaged PI3K inhibitor (IC50=18.92 nM) with anticancer properties. PI3K-IN-41 has potential to be used in precisely controlled cancer therapeutics. PI3K-IN-41 exhibits potent PI3K ihibition upon UV light irradiation, and enhances antitumor effect .
|
-
- HY-P5910A
-
|
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
Azurin p28 peptide TFA is a tumor-penetrated antitumor peptide. Azurin p28 peptide TFA redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide TFA induces apoptosis or cell cycle arrest. Azurin p28 peptide TFA inhibits p53-positive tumor growths. Azurin p28 peptide TFA shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .
|
-
- HY-13404
-
|
INC280; INCB28060
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-N2187
-
|
|
Bacterial
HIF/HIF Prolyl-Hydroxylase
PI3K
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
|
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .
|
-
- HY-13404B
-
|
INC280 hydrochloride; INCB-28060 hydrochloride
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-13404C
-
|
INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-13404A
-
|
INC280 dihydrochloride; INCB28060 dihydrochloride
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-122144
-
|
Teroxirone
|
Others
|
Cancer
|
|
α-Triglycidyl isocyanurate (Teroxirone) is an antitumor compound with activity to inhibit DNA replication. α-Triglycidyl isocyanurate exerts its anticancer effect by alkylating and cross-linking DNA. α-Triglycidyl isocyanurate is relatively stable in fresh human plasma and whole blood, showing good biocompatibility. The metabolism of α-Triglycidyl isocyanurate mainly occurs in rat liver and is metabolized through an NADPH-independent pathway. The cytotoxicity of α-Triglycidyl isocyanurate can be partially restored under specific conditions, suggesting the complexity of its metabolic pathway .
|
-
- HY-167854
-
|
|
Others
|
Cancer
|
|
KW-2450 Free base is a potent multikinase inhibitor targeting Aurora A and B kinases, demonstrating significant antitumor activity against triple-negative breast cancer (TNBC). KW-2450 Free base effectively reduces cell viability, promotes apoptosis, and inhibits colony formation and mammosphere formation in TNBC cells. KW-2450 Free base significantly suppresses the growth of TNBC xenografts, leading to tetraploid accumulation followed by apoptosis or the survival of octaploid cells. KW-2450 Free base enhances the efficacy of combination therapy with the MEK inhibitor selumetinib, resulting in a synergistic antitumor effect in TNBC models. KW-2450 Free base also acts as an orally bioavailable inhibitor of IGF-1R and IR tyrosine kinases, contributing to its potential antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis.
|
-
- HY-P10424
-
|
|
PD-1/PD-L1
|
Cancer
|
|
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research .
|
-
- HY-13404R
-
|
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (Standard) is the analytical standard of Capmatinib. This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-108052
-
|
Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride
|
EGFR
Apoptosis
Akt
|
Cardiovascular Disease
Cancer
|
|
Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .
|
-
- HY-158310
-
|
|
EGFR
Ras
|
Cancer
|
|
SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC50=42.13±1.55 nM) and EGFR(IC50=1.01±0.04 nM) by inhibiting their downstream effector molecules. SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50=0.45±0.03 μM) .
|
-
- HY-W050154R
-
|
|
Parasite
Tyrosinase
NF-κB
CDK
|
Infection
Inflammation/Immunology
Cancer
|
|
Kojic acid (Standard) is the analytical standard of Kojic acid. This product is intended for research and analytical applications. Kojic acid is a substance produced by Aspergillus oryzae, with various biological activities including antitumor, insecticidal, antibacterial, antioxidant, and radioprotective effects. Kojic acid exhibits tyrosinase inhibition activity by capturing copper ions that bind to the active site of tyrosinase, preventing its activation. Tyrosinase is a key enzyme in the biosynthesis of melanin, so kojic acid can block melanin production. Additionally, kojic acid shows potential inhibition of NF-κB activity in human keratinocytes, which may also be related to the anti-melanogenic effect induced by kojic acid. Kojic acid is effective when administered orally and can also be absorbed transdermally. Nano-carrier systems prepared with kojic acid demonstrate effective delivery of anticancer drugs. Kojic acid holds promise for research in cancer, infectious diseases, and skin whitening among other fields .
|
-
- HY-118138
-
|
|
Others
|
Cancer
|
|
NC-182 is a novel antitumor compound with a benzo[a]phenazine ring. The interaction mode of the agent with DNA and its effect on DNA conformation were systematically investigated by fluorescence, absorption and circular dichroism spectroscopy as well as viscosity titration measurements, and were compared with those of the DNA minor groove binder distamycin and the DNA base intercalator daunomycin. NC-182 was found to be a strong DNA intercalator, especially for B-form DNA, although without specificity for base pairs. The binding of NC-182 to B-DNA exhibited a biphasic behavior depending on the molar ratio of agent to DNA (r): at relatively low r values, NC-182 made the B-form structure rigid, and at higher r values, promoted the transition from B- to non-B-forms. NC-182 was also shown to promote the unwinding of Z-form DNA into B-form. Viscosity, UV 'melting' and circular dichroism experiments further showed that: (1) NC-182 intercalates to stabilize the DNA double helix structure; (2) NC-182 intercalates into the poly(dA) 2poly(dT) DNA structure to stabilize the triple helix structure, resulting in a melting point close to that of the double helix structure; the melting curves of the triple helix and double helix structures overlap at r > 0.06. These observations make an important contribution to our understanding of the biological properties of this novel benzo[a]phenazine derivative, which is a new antitumor agent suitable for both multiagent-resistant and sensitive tumors.
|
-
-
-
HY-L080
-
|
|
107 compounds
|
|
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.
There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.
MCE carefully collects a unique of 107 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.
|
| Cat. No. |
Product Name |
Type |
-
- HY-112624F1
-
|
|
Fluorescent Dyes/Probes
|
|
CY5-Dextran (MW 4000) is a fluorescent dye that consists of CY5 (HY-D0821) and Dextran (HY-112624) (Ex=633 nm; Em=670 nm). CY5-Dextran (MW 4000) exhibits an anti-tumor effect. CY5-Dextran (MW 4000) can be used to visualize the specific subcellular distribution of dextran at the nanoscale .
|
| Cat. No. |
Product Name |
Type |
-
- HY-W001925
-
|
|
Biochemical Assay Reagents
|
|
7-Methoxy-1-tetralone is a potent antitumor agent. 7-Methoxy-1-tetralone inhibits cancer cell proliferation and migration, and induces hepatocellular carcinoma cell (HCC) apoptosis. 7-Methoxy-1-tetralone decreased the protein levels of NF-κB, matrix metallopeptidase 2 (MMP2)/MMP9, and p-AKT. 7-Methoxy-1-tetralone showed antitumor activity in nude mice and had no effect on body weight and liver, spleen and organ index .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1812
-
AUNP-12
3 Publications Verification
NP-12
|
PD-1/PD-L1
|
Cancer
|
|
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
|
-
- HY-N6693
-
|
NSC 122023
|
Apoptosis
Antibiotic
Autophagy
Fungal
|
Infection
Others
Cancer
|
|
Valinomycin is a potassium-specific ionophore, the valinomycin-K + complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K + gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research .
|
-
- HY-P1812A
-
|
NP-12 TFA
|
PD-1/PD-L1
|
Cancer
|
|
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
|
-
- HY-P10652
-
|
|
Wnt
β-catenin
|
Cancer
|
|
hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research .
|
-
- HY-P5557
-
|
|
Bacterial
Necroptosis
|
Cancer
|
|
TP4 (Nile tilapia piscidin) is an orally active piscidin-like antimicrobial peptide. TP4 inhibits multiple gram positive and negative strains (MIC: 0.03-10 μg/mL). TP4 shows hemolytic activities. TP4 enhances immune response, antioxidant activity, and intestinal health against bacterial infections. TP4 also has anti-tumor effect, and induces necrosis by triggering mitochondrial dysfunction in cancer cells .
|
-
- HY-P10449
-
|
|
Peptides
|
Cancer
|
|
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .
|
-
- HY-P3358
-
|
|
Peptides
|
Cancer
|
|
Antitumor agent-39 is a peptide compound with anticancer effect (US20050009751A1, compound 64) .
|
-
- HY-P10087
-
|
Mouse TREM-1(213–221), GF9
|
Peptides
|
Cancer
|
|
Mouse TREM-1 SCHOOL peptide (Mouse TREM-1(213-221), GF9) targets interactions between TREM-1 and its signaling partner DAP-12, and inhibits TREM-1 signaling. Mouse TREM-1 SCHOOL peptide has antitumor effect .
|
-
- HY-P5910
-
|
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .
|
-
- HY-P5910A
-
|
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
Azurin p28 peptide TFA is a tumor-penetrated antitumor peptide. Azurin p28 peptide TFA redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide TFA induces apoptosis or cell cycle arrest. Azurin p28 peptide TFA inhibits p53-positive tumor growths. Azurin p28 peptide TFA shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .
|
-
- HY-P10424
-
|
|
PD-1/PD-L1
|
Cancer
|
|
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99179
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer .
|
-
- HY-P990076
-
|
14.18 mAb; hu14.18-IL2; EMD 273063
|
Inhibitory Antibodies
|
Cancer
|
|
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N1984
-
-
-
- HY-N4109
-
-
-
- HY-N0211
-
-
-
- HY-107226
-
-
-
- HY-N8840
-
-
-
- HY-N3512
-
-
-
- HY-N8204
-
-
-
- HY-N6049
-
-
-
- HY-N8684
-
-
-
- HY-N4109R
-
-
-
- HY-126775
-
-
-
- HY-N3665
-
-
-
- HY-113314
-
-
-
- HY-N0211R
-
-
-
- HY-128355A
-
-
-
- HY-N2515
-
-
-
- HY-N0405
-
-
-
- HY-N2515R
-
|
|
Panax ginseng C. A. Meyer
Triterpenes
Structural Classification
Terpenoids
Source classification
Plants
Araliaceae
|
NF-κB
PI3K
JAK
Apoptosis
|
|
Ginsenoside Rk1 (Standard) is the analytical standard of Ginsenoside Rk1. This product is intended for research and analytical applications. Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures .
Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB .
Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis .
Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
|
-
-
- HY-N1346
-
-
-
- HY-N0405R
-
-
-
- HY-119527
-
-
-
- HY-N1366
-
-
-
- HY-129234
-
-
-
- HY-N1346R
-
|
|
Structural Classification
Flavonoids
Flavones
Leguminosae
Plants
Vigna unguiculata
|
Toll-like Receptor (TLR)
Apoptosis
|
|
Robinin (Standard) is the analytical standard of Robinin. This product is intended for research and analytical applications. Robinin is a flavonoid that can be extracted from the leaves of purple cowpea, inhibiting TGF-β, TLR4/NF-κB and TLR2-PI3k-AKT signaling pathways. Robinin exerts anti-inflammatory and anti-tumor effects. The combination of Robinin and Methotrexate (HY-14519) reduces inflammation in experimental arthritis, Robinin can decrease the Doxorubicin (HY-15142A) induced cardiac toxicity effect .
|
-
-
- HY-129071
-
-
-
- HY-19825
-
-
-
- HY-129071R
-
-
-
- HY-N7271
-
-
-
- HY-59208
-
-
-
- HY-N1318
-
-
-
- HY-125117
-
-
-
- HY-123325
-
-
-
- HY-N2150
-
-
-
- HY-N0646
-
-
-
- HY-N2112
-
-
-
- HY-B0220
-
-
-
- HY-W001925
-
-
-
- HY-N6693
-
-
-
- HY-B0220D
-
-
-
- HY-B0220C
-
|
|
Classification of Application Fields
Disease Research Fields
Cancer
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
|
Erythromycin aspartate is a macrolide antibiotic produced by actinomycete?Streptomyces erythreus?with a broad spectrum of antimicrobial activity. Erythromycin aspartate binds to bacterial 50S ribosomal subunits and inhibits?RNA-dependent protein synthesis?by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin aspartate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-N0646R
-
-
-
- HY-155851
-
-
-
- HY-N2187
-
-
-
- HY-108052
-
-
-
- HY-W050154R
-
|
|
Structural Classification
Human Gut Microbiota Metabolites
Microorganisms
Ketones, Aldehydes, Acids
Source classification
Endogenous metabolite
|
Parasite
Tyrosinase
NF-κB
CDK
|
|
Kojic acid (Standard) is the analytical standard of Kojic acid. This product is intended for research and analytical applications. Kojic acid is a substance produced by Aspergillus oryzae, with various biological activities including antitumor, insecticidal, antibacterial, antioxidant, and radioprotective effects. Kojic acid exhibits tyrosinase inhibition activity by capturing copper ions that bind to the active site of tyrosinase, preventing its activation. Tyrosinase is a key enzyme in the biosynthesis of melanin, so kojic acid can block melanin production. Additionally, kojic acid shows potential inhibition of NF-κB activity in human keratinocytes, which may also be related to the anti-melanogenic effect induced by kojic acid. Kojic acid is effective when administered orally and can also be absorbed transdermally. Nano-carrier systems prepared with kojic acid demonstrate effective delivery of anticancer drugs. Kojic acid holds promise for research in cancer, infectious diseases, and skin whitening among other fields .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-160263S
-
|
|
|
BET-IN-22 (compound 231) has anti-tumor effect .
|
-
-
- HY-131126S
-
|
|
|
Metolcarb-d3 is the deuterium labeled Herniarin. Herniarin is a natural coumarin occurs in some flowering plants, with antitumor effect.
|
-
-
- HY-N1318S
-
|
|
|
Salvigenin-d9 is the deuterium labeled Salvigenin. Salvigenin is a natural polyphenolic compound, with neuroprotective effect. Salvigenin has antitumor cytotoxic and immunomodulatory properties[1][2].
|
-
-
- HY-B0220S2
-
|
|
|
Erythromycin-d3 is the deuterium labeled Erythromycin[1]. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid. Erythromycin also exhibits antitumor and neuroprotective effect in different fields of research[2][3][4][5].
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-W440983
-
|
PC(18:0/22:6); DHA-PC; 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine
|
|
Phospholipids
|
|
SDPC (DHA-PC) is a new generation of omega-3 lipids, which contains an ester bond linking DHA at the sn-2 position of phospholipid. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine exerts anti-angiogenesis effect through activating PPARγ. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine significantly declines the proliferation, migration, tube formation of human umbilical vein endothelial cells. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine has the potential for anti-tumor angiogenesis research .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
